ALX Oncology (NASDAQ: ALXO) awards 800,000 options to chief officer

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. reported that Chief Development & Operating Officer Jeff E. Knight received a grant of stock options covering 800,000 shares of Common Stock. The options have an exercise price of $1.68 per share and expire on April 15, 2036.

According to the vesting terms, one-fourth of the options vest on April 13, 2027 and the remaining options vest in equal monthly installments over the following three years. After this grant, Knight holds 800,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Knight Jeff E.

Role Chief Dev & Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	800,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 800,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 800,000 stock options Exercise price: $1.68 per share Underlying shares: 800,000 shares +3 more

6 metrics

Options granted 800,000 stock options Grant to Chief Dev & Operating Officer on 2026-04-16

Exercise price $1.68 per share Exercise price for underlying Common Stock

Underlying shares 800,000 shares Common Stock underlying the granted options

Vesting cliff 25% on April 13, 2027 One-fourth of options vest on this date

Ongoing vesting 1/48 monthly thereafter Remaining options vest in equal monthly installments

Expiration date April 15, 2036 Final expiration of the stock option grant

Key Terms

Stock option (right to buy), Common Stock, Grant, award, or other acquisition, vest, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest financial

"One-fourth of the shares subject to the option vest on April 13, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"expiration_date: 2036-04-15T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knight Jeff E.

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Dev & Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$1.68	04/16/2026		A		800,000		(1)	04/15/2036	Common Stock	800,000	$0	800,000	D

Explanation of Responses:

1. One-fourth of the shares subject to the option vest on April 13, 2027 and 1/48th vest monthly thereafter.

	/s/ Shelly Wong, by power of attorney	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ALXO report for Jeff E. Knight?

ALX Oncology reported that Chief Development & Operating Officer Jeff E. Knight received a grant of stock options for 800,000 shares of Common Stock. These options were awarded at an exercise price of $1.68 per share and represent a compensation-related acquisition, not an open-market trade.

What is the exercise price of Jeff E. Knight’s new ALXO stock options?

The granted stock options have an exercise price of $1.68 per share for the underlying Common Stock. This means Knight can buy up to 800,000 shares at $1.68 once the options vest, regardless of the future market price, until the options expire.

How do the 800,000 ALXO stock options granted to Jeff E. Knight vest?

The options vest over time. One-fourth of the 800,000 options vest on April 13, 2027, with the remaining three-fourths vesting in equal monthly installments thereafter. This schedule encourages long-term alignment between Knight and ALX Oncology’s performance and retention over several years.

When do Jeff E. Knight’s ALXO stock options expire?

The stock options granted to Jeff E. Knight expire on April 15, 2036. Until that expiration date, and subject to the vesting schedule, Knight may choose to exercise vested options to purchase ALX Oncology Common Stock at the fixed exercise price of $1.68 per share.

How many ALXO stock options does Jeff E. Knight hold after this grant?

Following this award, Jeff E. Knight holds a total of 800,000 stock options directly. All of these options relate to ALX Oncology Common Stock, carry an exercise price of $1.68 per share, and are subject to the time-based vesting and final expiration date disclosed.